Description
Indications
Used to treat idiopathic pulmonary fibrosis (IPF) in adults, chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype in adults, and to slow the decline of lung function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Mécanisme d’action
, RTK nRTK RTK PDGFR α β FGFR 1 3 VEGFR 1 3 1 CSF1R Fms -3 FLT-3 FLT-3 , ILD ATP , , ILD
Pharmacologie
12.1 Mecanisme d action , (RTK) (nRTK) RTK (PDGFR) α β (FGFR) 1 3 (VEGFR) 1 3 1 (CSF1R) Fms -3 (FLT-3) FLT-3 , (ILD) (ATP) ,
Precautions
5.1 Child-Pugh B Child-Pugh C [ (8.6) (12.3)] Child-Pugh A [ Posologie (2.3)] 5.2 DILI , DILI
Interactions médicamenteuses
7.1 P- (P-gp) CYP3A4 P-gp , CYP3A4 [ (12.3)] P-gp CYP3A4 , 60% P-gp CYP3A4 [ (12.3)] ,
Effets indésirables
[ Precautions(5.2)] [ Precautions(5.3)] - [ Precautions(5.4)] [ Precautions(5.5)] [ Precautions(5.6)] [ Precautions(5.7)] [ Precautions(5.8)] 6.1 ,



